Moreover, an EP4-selective agonist activated the PI3K/ERK pathway in colon carcinoma cells possibly via EGFR transactivation and thereby rescued proliferation suppressed by indomethacin or COX-2 inhibitors [203]. This evidence concerns the gene PTGS2 and colon carcinoma.